IGFBP7 and acute kidney injury: The discriminative performance of [TIMP-2]*[IGFBP7] was also assessed in the subgroup of 90 patients presenting moderate to severe AKI at inclusion, considering persistent AKI as a KDIGO stage ≥ 2 at 72 h.